Apogenix to Present New Data on Asunercept at ESMO Immuno-Oncology Congress
Apogenix, a biopharmaceutical company developing next generation immuno-oncology therapeutics, announced today that new data on its lead immuno-oncology candidate asunercept will be presented in a poster at the ESMO Immuno-Oncology Congress 2019, held from December 11-14, 2019, at the Palexpo in Geneva, Switzerland. The data are the result of a research collaboration with Benoit Van den Eynde and his team from the Ludwig Institute for Cancer Research in Brussels, Belgium.